Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with m...
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
About this item
Full title
Author / Creator
Lenz, Georg , Hawkes, Eliza , Verhoef, Gregor , Haioun, Corinne , Thye Lim, Soon , Seog Heo, Dae , Ardeshna, Kirit , Chong, Geoffrey , Haaber, Jacob , Shi, Wei , Gorbatchevsky, Igor , Lippert, Susanne , Hiemeyer, Florian , Piraino, Paolo , Beckmann, Georg , Peña, Carol , Buvaylo, Viktoriya , Childs, Barrett H. and Salles, Gilles
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol 3-kinase inhibitor copanlisib in patients with relapsed/refractory DLBCL and assessed the relationship between efficacy and DLBCL cell of origin (COO; activated B-cell like [ABC] and germina...
Alternative Titles
Full title
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7387311
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7387311
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/s41375-020-0743-y
